Last reviewed · How we verify

Teneli (Teneligliptin)

Tanabe Pharma Corporation · FDA-approved active Small molecule

Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.

Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals. Used for Type 2 diabetes mellitus.

At a glance

Generic nameTeneli (Teneligliptin)
SponsorTanabe Pharma Corporation
Drug classDPP-4 inhibitor
TargetDPP-4 (Dipeptidyl peptidase-4)
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

By blocking DPP-4, teneligliptin prevents the degradation of GLP-1 and GIP, endogenous hormones that stimulate glucose-dependent insulin release and suppress glucagon secretion. This mechanism lowers postprandial and fasting blood glucose levels in patients with type 2 diabetes without causing hypoglycemia when used as monotherapy, since insulin secretion is glucose-dependent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: